Prof Giancarlo Agenelli speaks to ecancer at the International Aspirin Foundation Scientific Conference 2019 in Rome about the effectiveness of combining antiplatelet and anticoagulant strategies in high-risk patients.

He describes data from a clinical trial which evaluated the combination of low-dose aspirin and low-dose rivaroxaban.

Prof Agnelli also discusses additional measures that could reduce adverse events such as cardiovascular death and death and whether these should be incorporated into clinical guidelines.

Read more on the highlights from the 2019 International Aspirin Foundation Scientific Conference here.